Αποτελέσματα Αναζήτησης
This paper summarizes current knowledge on ionizing radiation-associated breast cancer in the context of established breast cancer risk factors, the radiation dose–response relationship, and modifiers of dose response, taking into account epidemiological studies and animal experiments.
- Radiation Therapy for Early-Stage Breast Cancer
Other significant risk factors include age at menarche, age...
- Radiation Therapy for Early-Stage Breast Cancer
19 Ιαν 2023 · The most common early side effects of radiation therapy in breast cancer patients are skin irritation and fatigue. Radiation therapy can last anywhere from one to six weeks. As you get farther into treatment, the skin on the breast or chest that’s repeatedly exposed to radiation can start to look dry or red and feel irritated.
23 Οκτ 2024 · Find out why doctors use radiation treat breast cancer. Learn what to expect and the side effects of breast cancer radiation, including proton therapy.
15 Οκτ 2021 · Radiation therapy (RT) is an essential component in the management of breast cancer. Following breast-conserving surgery (BCS), adjuvant RT is the standard of care for most patients. Traditionally, RT was delivered with standard whole breast irradiation (WBI) over 5-7 weeks following BCS.
24 Απρ 2020 · Radionuclide imaging using breast-specific gamma imaging, molecular breast imaging, and positron emission mammography expose of all organs of the body to ionizing radiation and therefore pose significantly higher risks of radiation-caused cancers and cancer deaths than DM and DBT.
17 Ιουλ 2023 · Other significant risk factors include age at menarche, age at menopause, age at first pregnancy, family history, use of exogenous estrogen, alcohol consumption, prior history of chest irradiation, benign proliferative breast disease, mammographic breast density, and genetic mutations.
24 Οκτ 2022 · A three-week course of radiation therapy is as safe and effective as four to six weeks of treatment for patients with early-stage breast cancer who have a higher risk of having their tumors recur, results of a randomized phase III clinical trial show.
